Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rozrolimupab

Next Previous
Drug Profile

Rozrolimupab

Alternative Names: Anti-RhD; Anti-Rhesus D; Anti-rhesus D immunoglobulin Gs; Anti-rhesus D polyclonal antibodies; Sym-001; Symphoglobulin-D

Latest Information Update: 09 Jun 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Symphogen
  • Class Immunoglobulins; Polyclonal antibodies; Recombinant proteins
  • Mechanism of Action Rh-Hr blood group system inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Haemolytic disease of newborn; Idiopathic thrombocytopenic purpura

Most Recent Events

  • 04 Jun 2020 Symphogen has been acquired by Servier
  • 01 May 2013 Rozrolimupab is considered to be outside Symphogen's oncology focus, and its further development is dependent on identification of a global partner
  • 01 May 2013 Suspended - Phase-II for Haemolytic disease of newborn in Germany (IM)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top